Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

Q2 2025 Management View CEO Reshma Kewalramani highlighted "very strong performance across the board, growing and diversifying revenue with multiple new product launches," noting $2.96 billion in ...